Press Releases and Statements

CHPA issued the following statement following the Food and Drug Administration’s announcement of a public meeting to gather stakeholder input on the potential development of a user fee program for nonprescription monograph drugs.

CHPA applauds the state of Georgia for becoming the thirty-third state to adopt the real-time, stop-sale technology called the National Precursor Log Exchange (NPLEx).

CHPA, which represents leading manufacturers of OTC cough medicines, strongly supports this legislation and is joined many by substance abuse prevention organizations such as the Community Anti-Drug Coalitions of America and the Partnership for Drug-Free Kids.

CHPA spoke today before a Food and Drug Administration Advisory Nonprescription Drugs Advisory Committee, during which the committee discussed data submitted by Galderma Laboratories, L.P. to support the supplemental new drug application for over-the-counter marketing of adapalene gel 0.1%.

CHPA released the following statement today in support of a Florida law prohibiting the sale of OTC medicines containing the cough suppressant dextromethorphan (DXM) to minors.

CHPA elected officers and members to its Board of Directors at the association’s Annual Executive Conference, held March 14 through 16 at the Turnberry Isle Miami in Aventura, Florida.

CHPA commends the U.S. House of Representatives for swift passage of the Microbead-Free Waters Act of 2015 (H.R. 1321).

CHPA President and CEO Scott Melville released the following statement today regarding this afternoon’s House Energy and Commerce (E&C) Committee passage of the Microbead-Free Waters Act of 2015.

New members of the Consumer Healthcare Products Association (CHPA) Board of Directors were elected at the association’s board of directors meeting, held November 17 in Washington, D.C.